The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors-Reference-Cited by-同舟云学术

The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors

Published:2018-03-29 Issue:5 Volume:218 Page:698-706
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Pham Hanh T¹²,Labrie Lydia¹²,Wijting Ingeborg E A³,Hassounah Said¹⁴,Lok Ka Yee¹,Portna Inna¹²,Goring Mark E¹⁴,Han Yingshan¹,Lungu Cynthia⁵,van der Ende Marchina E³,Brenner Bluma G¹⁶,Boucher Charles A⁵,Rijnders Bart J A³,van Kampen Jeroen J A⁵,Mesplède Thibault¹²⁴,Wainberg Mark A¹²⁴

Affiliation:

1. McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada

2. Department of Microbiology and Immunology, McGill University, Montreal, Canada

3. Department of Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands

4. Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, Canada

5. Department of Viroscience, Erasmus University, Rotterdam, Netherlands

6. Faculty of Surgery, McGill University, Montreal, Canada

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/218/5/698/25206878/jiy175.pdf

Reference50 articles.

1. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer;Engelman;Cell,1991

2. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells;Hazuda;Science,2000

3. Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia;Katlama;J Antimicrob Chemother,2016

4. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial;Sax;Lancet HIV,2017

5. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study;Raffi;Lancet,2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dolutegravir resistance in sub-Saharan Africa: should resource-limited settings be concerned for future treatment?;Frontiers in Virology;2023-09-25

2. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration;Antimicrobial Agents and Chemotherapy;2023-05-17

3. Transmission of S230R integrase drug resistance mutation affecting second-generation integrase inhibitors in a French primary HIV-1 infected man;Journal of Antimicrobial Chemotherapy;2023-05-06

4. Machine learning aided multiscale modelling of the HIV-1 infection in the presence of NRTI therapy;PeerJ;2023-03-31

5. Structure of a HIV-1 IN-Allosteric inhibitor complex at 2.93 Å resolution: Routes to inhibitor optimization;PLOS Pathogens;2023-03-03